Data on patient experiences with new drugs and therapies promises to play a prominent role in drug reviews and approval. Analysis of this information could help identify and address adverse drug reactions and safety problems before they occur. Currently, these problems cost the industry nearly $30 billion per year. Saba Darvesh at Veeva Systems talks about the safety of patient information.